https://orcid.org/0000-0001-9622-169X
References
- Trifirò G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug Saf. 2018 Feb;41(2):143–149.
- Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427–436.
- Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30(7):623–625.
- Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Therapeutic innovation and regulatory science. Drug Inf J. 2008;42(5):409–419.
- Bergvall T, Norén GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014 Jan;37(1):65–77.
- Patadia VK, Schuemie MJ, Coloma P, et al. Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm. 2015 Feb;37(1):94–104.
- Liu M, Hu Y, Tang B. Role of text mining in early identification of potential drug safety issues. Methods Mol Biol. 2014;1159:227–251.
- Avillach P, Coloma PM, Gini R, et al. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc. 2013 Jan 1;20(1):184–192.
- Sultana J, Trotta F, Addis A, et al. Healthcare database networks for drug regulatory policies: international workshop on the Canadian, US and Spanish experience and future steps for Italy. Drug Saf. 2020 Jan;43(1):1–5.
- Trifirò G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014 Jun;275(6):551–561.
- Coloma PM, Schuemie MJ, Trifirò G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1–11.
- Yih WK, Maro JC, Nguyen M, et al. Assessment of quadrivalent human papillomavirus vaccine safety using the self-controlled tree-temporal scan statistic signal-detection method in the sentinel system. Am J Epidemiol. 2018 Jun 1;187(6):1269–1276.
- Pacurariu AC, Straus SM, Trifirò G, et al. Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection. Drug Saf. 2015 Dec;38(12):1201–1210.
- Furlan G, Edwards B, Mastroianni A, et al. The future of pharmacovigilance: proposals for more efficient and effective systems-based approaches. Pharm Med. 2016;30:137.
- Orre R, Bate A, Norén GN, et al. A bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets. Int J Neural Syst. 2005 Jun;15(3):207–222.
- Pierce CE, Bouri K, Pamer C, et al. Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts. Drug Saf. 2017;40(4):317–331.
- Caster O, Dietrich J, Kürzinger ML, et al. Assessment of the utility of social media for broad-ranging statistical signal detection in pharmacovigilance: results from the WEB-RADR project. Drug Saf. 2018 Dec;41(12):1355–1369.
- Sarker A, Ginn R, Nikfarjam A, et al. Utilizing social media data for pharmacovigilance: a review. Biomed Inform. 2015;54:202–212.
- van Stekelenborg J, Ellenius J, Maskell S, et al. Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR. Drug Saf. 2019 Dec;42(12):1393–1407.
- Arnaud M, Bégaud B, Thurin N, et al. Methods for safety signal detection in healthcare databases: a literature review. Expert Opin Drug Saf. 2017 Jun;16(6):721–732.
- Wang SV, Maro JC, Baro E, et al. Data mining for adverse drug events with a propensity score-matched tree-based scan statistic. Epidemiology. 2018 Nov;29(6):895–903.
- Pottegård A, Klungel O, Winterstein A, et al. The international society for pharmacoepidemiology’s comments on the core recommendations in the summary of the Heads of Medicines Agencies (HMA) - EMA joint big data task force. Pharmacoepidemiol Drug Saf. 2019 Oct 22; DOI:10.1002/pds.4911.
- Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open. 2018 Jan 23;8(1):e019759.